Neurocrine Announces Positive Results from Phase III Kinect 3 Study of NBI-98854 in Tardive Dyskinesia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Leerink Partners Raises Price target on Neurocrine Biosciences (NBIX) Following Positive KINECT3 Results
October 8, 2015 2:49 PM EDTLeerink Partners reiterated an Outperform rating on Neurocrine Bio. (NASDAQ: NBIX), and raised the price target to $71.00 (from $67.00), following positive KINECT3 results. Analyst Paul Matteis We sees the likelihood of the emergence of an unexpected long-term safety signal as very low, but still possible given the patient population under surveillance.
Matteis commented, "On the heels of positive... More
Neurocrine Bio (NBIX) PT Raised to $96 at Piper Jaffray
October 8, 2015 10:52 AM EDTPiper Jaffray analyst Charles C. Duncan reiterated an Overweight rating and boosted his price target on Neurocrine Bio. (NASDAQ: NBIX) to $96.00 (from $86.00).
Duncan commented, "Today Neurocrine announced positive Phase III results on '854 in Tardive Dyskinesia patients with an underlying psychiatric disorder. Although... More
Neurocrine Biosciences (NBIX) Announces Significant Data from NBI-98854 Kinect 3 in Lardive Dyskinesia
October 8, 2015 6:34 AM EDTNeurocrine Biosciences (NASDAQ: NBIX) announced that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying... More
